NCT00140725View on ClinicalTrials.gov

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 30, 2000

Conditions
Chronic Hepatitis B
Interventions
DRUG

Lamivudine plus Polyethylene glyco-interferon alfa-2b

DRUG

Lamivudine

Trial Locations (1)

Unknown

GSK Investigational Site, Shatin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY